Not Signed In -
Pneumonia |
|
|
Clinical Trial: Comparison of Telavancin and Vancomycin for Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus Aureus (ATTAIN 2)
This study is currently recruiting patients.
|
Purpose
Study 0019 compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
| Condition | Intervention | Phase |
|---|---|---|
| Bacterial Pneumonia | Drug: Telavancin | Phase III |
MedlinePlus related topics: Bacterial Infections; Pneumonia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus On Patients with Infections Due to Methicillin-Resistant Staphylococcus Aureus
Further Study Details:
Primary Outcomes: Clinical response
Expected Total Enrollment: 625
Expected Total Enrollment: 625
Study start: January 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic-care facility
Exclusion Criteria:
- Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy prior to randomization
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00124020
Claudia Fuentes 650 808 6094 cfuentes@theravance.com
Ohio
Regional Infectious Diseases-Infusion Center, Lima, Ohio, 45801, United States; Recruiting
R. Scott Steinecker, MD
Study chairs or principal investigators
Ralph G. Corey, MD, Principal Investigator, Duke Clinical Research Center
More Information
Study ID Numbers: 0019
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 25, 2005
ClinicalTrials.gov Identifier: NCT00124020
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-26
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 25, 2005
ClinicalTrials.gov Identifier: NCT00124020
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-26
email this page
print this page
bookmark this page
feedback on this page
